What Public GLP-1 Provider Documents Can—and Cannot—Prove

A GLP-1 provider’s website can be precise about a starting price and vague about who will answer a medical question. It can name a clinical group without independently establishing that group’s credentials. For adults comparing U.S. telehealth programs, the useful question is not simply whether a website contains evidence. It is what kind of evidence each document supplies—and whether the conclusion being drawn stays within those limits.

This guide examines public documentation from CoreAge Rx, Ro, Enhance.MD, Sesame, Walgreens and Found, consulted October 19, 2026. That is the consultation date, not necessarily each page’s update date. These examples show how to separate documented commercial offers and service processes from unverified performance claims. Contradictory pages are especially informative: they identify questions that remain unresolved, rather than giving readers permission to choose whichever promise sounds best.

At a glance

A platform is not necessarily the medical practice: CoreAge Rx assigns medical evaluations, treatment planning and prescribing to named independent professional entities, while describing its platform operator as an administrative coordinator.
Sources: [20]
Membership does not necessarily include medication: Ro explicitly excludes medication from the Ro Body membership fee; Sesame similarly separates its subscription from medication costs.
Sources: [7] [30]
A support heading needs its explanatory text: CoreAge Rx uses a “24/7 Provider Support” heading, but the accompanying description refers to its customer support team.
Sources: [24]
Quality claims need attribution: Found states that its compounded semaglutide undergoes third-party testing for potency, purity and sterility. The consulted documentation does not identify the testing laboratory or provide certificates of analysis.
Sources: [18]
Regulatory evidence has a defined scope: FDA says compounded preparations are not FDA approved and recommends their use when an individual’s medical needs cannot be met by an approved drug.
Sources: [1]

Start with the claim, not the logo

Public documents can establish that a company made a particular representation. They do not automatically establish that the representation has been independently verified. Enhance.MD’s FAQ says its clinical team consists of U.S.-licensed physicians and nurse practitioners. Found says every clinician is board-certified and trained in metabolic medicine. Those are meaningful claims to record and investigate, but neither statement is a substitute for checking the individual professional’s credentials.

The same distinction applies to geography. Enhance.MD says it is licensed in all 50 states, then lists a narrower set of service locations based on product availability. Walgreens publishes different state exclusions on its general weight-management and Medicare Bridge pages. These documents establish what the companies say about access, not a definitive operational map. A careful comparison preserves the disagreement and asks which rule applies to the patient’s location and requested service.

Match the document to the conclusion it can support
Public statement	What it documents	What remains unverified
Named medical group	The stated allocation of clinical responsibility	Individual credentials and actual care quality
Starting monthly price	An advertised entry point under stated conditions	The patient’s final checkout total
Third-party testing claim	The provider’s description of quality controls	Batch-specific results without supporting records
24/7 access	An advertised communication channel	Immediate response by a prescriber
Drug trial citation	Research on the studied product and population	The telehealth company’s treatment outcomes

Sources: [15] [14] [19] [34]

Map who actually performs each service

CoreAge Rx’s legal footer names M & D Integrations Inc d/b/a MD Integrations, MDI Medical Group P.C., and MD Integrations & Wellness Provider Group P.A. as the independent entities responsible for medical services. It describes DSO Fine Shrimp d/b/a CoreAgeRx as providing technology and administrative coordination, not medical care or clinical decisions. That division helps identify responsibility; it does not independently verify the entities’ licensing or performance.

Other providers describe similar separations with different details. Enhance.MD identifies itself as an administrative platform, while its terms include EnhanceMD CA, PC alongside groups named elsewhere. Sesame says affiliated practices operate independently and explicitly states that Sesame is not a pharmacy. Walgreens assigns clinical control to independent medical practices rather than its administrative company. Readers should identify the practice, prescriber and dispensing pharmacy separately instead of assuming one brand performs every task.

Sources: [20] [13] [23] [10] [11] [12]

Treat enrollment steps as process evidence

A documented intake sequence is more useful than a broad promise of personalized care. Ro requests medical history, lifestyle information and goals; its provider may request metabolic testing before recommending a plan. Sesame describes choosing a provider and discussing history and goals by video, with laboratory testing if metabolic information is needed. Both describe clinical decisions rather than guaranteed prescriptions. These details help readers prepare for enrollment without predicting whether treatment will be offered.

Enhance.MD provides a more specific laboratory example: its process page describes Quest Diagnostics testing for a comprehensive metabolic panel, TSH, lipids and hemoglobin A1c before consultation. Its FAQ requires identity verification using a full-face photograph and government-issued ID, then describes scheduling video consultation after laboratory results arrive. Other simplified onboarding descriptions omit testing, so the applicable sequence needs confirmation. Detailed steps are evidence of an advertised workflow, not proof that every patient follows an identical path.

Sources: [17] [29] [30] [11] [6] [15]

Read prices as conditional offers, not clinical evidence

CoreAge Rx advertises compounded semaglutide from $79 monthly and compounded tirzepatide from $129 monthly, with supplies included, the same price at every dose and free shipping. A separate homepage block advertises compounded GLP-1s from $99 monthly. The consulted documentation does not establish the supply quantities or purchase conditions behind each minimum. Those are real advertised prices worth reporting, but they are neither individualized quotes nor evidence that one program produces better outcomes.

Ro illustrates a different structure: Ro Body costs $39 for the first month, then $149 monthly on the monthly plan, or as low as $74 monthly equivalent with annual prepayment. Medication is separate; the membership includes provider messaging, check-ins, coaching, insurance assistance and laboratory testing if necessary. Walgreens instead advertises initial visits from $49 without a subscription, with follow-up chat visits and additional video visits at $49 each, excluding medication. Neither structure establishes comparative clinical value.

Sources: [20] [7] [19]

Use contradictions to identify unresolved obligations

CoreAge Rx’s FAQ promises an automatic 100% refund if a provider does not approve a prescription. Its refund policy instead says an applicable $50–$100 consultation fee is nonrefundable, with the refundable treatment or medication portion returned. The policy also makes prescription sales final once approved by a provider and transmitted to the pharmacy, even before shipment. It separately states that orders become nonrefundable 30 calendar days after purchase even if incomplete or unshipped, except where applicable law requires otherwise. These restrictions should be clarified alongside the FAQ’s refund promise. The FAQ also describes both payment before medical review and medication billing at shipment. These are material inconsistencies. Public documentation can demonstrate the conflict, but it cannot establish which payment sequence or refund calculation a particular purchaser will encounter.

Billing intervals deserve the same scrutiny. Sesame advertises a $99 month-to-month option, while another passage specifies advance billing every 28 days. Its program page permits cancellation before the next cycle, but general terms require email or telephone cancellation at least 48 hours before renewal processing. Enhance.MD’s FAQ describes 28-day renewal even though product pages offer longer billing intervals. Four weeks is not a calendar month, and a plan label alone does not establish supply quantity or minimum commitment.

Sources: [16] [8] [30] [11] [9] [15]

Keep clinical studies separate from provider performance

A medication study and a company performance report answer different questions. STEP 1 and SURMOUNT-1 studied specified subcutaneous products, trial populations and treatment conditions; they were not evaluations of these telehealth services. Their findings do not establish outcomes for a provider’s compounded preparation, vitamin blend, different route or microdosing offer. Our guide to why a clinical trial is not a company performance report explains why transferring results across those boundaries can mislead.

Formulation details are therefore substantive, not cosmetic. CoreAge Rx says its compounded tirzepatide is typically formulated with B-12, with a formulation without B-12 subject to provider discussion. Enhance.MD markets Elite as an injectable semaglutide-and-tirzepatide combination. These descriptions document offerings, not independent evidence of efficacy or superior tolerability. The distinction between approved medicines and compounded preparations matters: compounded drugs are not FDA approved, but nonapproval alone does not prove clinical inequivalence. FDA recommends them when individual medical needs cannot be met by an approved drug.

Sources: [3] [4] [1] [16] [35]

Ask what testing and shipping claims leave out

Found says it works exclusively with 503A compounding pharmacies and that compounded semaglutide is tested externally for potency, purity and sterility before shipment. The consulted documentation does not identify the laboratory or include certificates of analysis. That supports reporting a provider-attributed quality-control claim, not declaring the dispensed product independently verified. Likewise, naming a pharmacy partner does not establish which pharmacy will fill a particular prescription or whether that pharmacy also compounds it.

Delivery promises require distinct milestones. Ro says cash-pay prescriptions sent to its own or partner pharmacies ship within a week once prescribed; that is dispatch, not arrival. CoreAge Rx estimates arrival approximately two to three business days after pharmacy shipment, separate from prior review and preparation. Neither statement establishes a cold-chain record. When reading delivery and refrigeration claims, retain FDA’s explicit instruction: do not use an injectable GLP-1 that arrives warm or inadequately refrigerated; contact the provider or dispensing pharmacy.

Sources: [18] [26] [8] [1]

Distinguish an open messaging channel from ongoing care

CoreAge Rx advertises ongoing provider access, but its “24/7 Provider Support” description refers to customer support staff. Its help center routes medical questions through the portal’s Talk to the Doctor function and billing or technical questions to support@coreagerx.com. Walgreens separately advertises round-the-clock pharmacy-expert chat, which may involve waiting and is not for emergencies. That pharmacy channel does not establish immediate prescriber access, and its availability does not establish a zero fee.

Found says its team follows up monthly for compounded tirzepatide, while identifying Aimee, its 24/7 digital companion, as AI rather than a continuously available clinician. Ro advertises unlimited provider messaging and regular check-ins without a numerical response deadline in the consulted documentation. These differences make clinical follow-up a separate evidence question. NIDDK describes follow-up as addressing tolerance and response; access to a portal, automated tool or renewal notice alone does not document that clinical work.

Sources: [24] [32] [27] [5] [28] [29] [2]

Questions & answers

Does CoreAge Rx document which pharmacy I can use?

Not consistently. Its FAQ requires prescriptions to be filled through affiliated pharmacies and says a local pharmacy cannot currently be used. Its terms allow a pharmacy chosen by the patient if requested at support@coreagerx.com before completing the order. The FAQ also says pharmacy assignment depends on therapy and medication. Ask for the dispensing pharmacy’s identity and the applicable channel restriction before purchasing.

Sources: [16] [22]

Does Ro’s insurance checker establish coverage or treatment eligibility?

No. Ro says the checker collects coverage information, does not request treatment and does not write prescriptions. Its insurance coordination currently covers Wegovy pen, Zepbound autoinjector pen and Ozempic, not every listed product. Ro also says Medicaid and some other government-funded plans make patients ineligible for treatment, while certain cash-pay options may remain available for Medicare, Medicare supplement or TRICARE members.

Sources: [25] [26]

Does Enhance.MD’s pharmacy list verify my dispensing arrangement?

It provides leads, not a patient-specific assignment. The FAQ names Tru Meds Rx, Strive Pharmacy and Pharmacy Hub; the terms name Rite-Away Pharmacy, Vios Compounding Pharmacy and TruMedsRx, plus other pharmacies. The FAQ requires a physical shipping address. It also permits a chosen pharmacy, but says medication costs are billed directly in that arrangement. Confirm the current pharmacy and resulting charges for the particular prescription.

Sources: [15] [23]

Does Sesame include every laboratory charge?

No. Its program documentation includes laboratory work performed at Quest Diagnostics except facilities in Arizona, Hawaii, North Dakota, New Jersey, New York, Oklahoma, Rhode Island, South Dakota and Wyoming. In those states, laboratory fees are additional to the subscription. That exception concerns included laboratory costs; it should not be repurposed as a complete map of program availability.

Sources: [30]

Does Walgreens’ no-subscription model mean there are no recurring arrangements?

Not necessarily. The general consultation offer requires no subscription, but its Medicare Bridge page says approved Walgreens prescriptions will be set up to autofill the following month. Those are different arrangements. The consulted documentation does not establish the procedure for disabling Bridge autofill. The page also allows eligible Bridge prescriptions to be filled at Walgreens or another pharmacy chosen by the patient.

Sources: [19] [34]

Does Found’s “with insurance” compounded price mean insurance pays for the drug?

No. Found’s terms connect that pricing to insurance coverage for clinical care, with possible copays, coinsurance and deductibles. Its billing consent makes the patient responsible for compounded GLP-1 charges and prohibits submitting those amounts to insurance. Insured care also requires synchronous video visits before each refill, generally with a separate visit copay. The label therefore needs to be read alongside the billing consent, not as drug-coverage confirmation.

Sources: [21] [33] [31]

Our assessment

Public provider documents are valuable evidence of advertised services, assigned responsibilities and stated payment boundaries. They are weaker evidence of actual execution and cannot independently establish licensing, product quality or clinical outcomes. The practical approach is to preserve specific prices and restrictions, identify disagreements, and request written clarification of the terms that affect enrollment. None of the examples here supports ranking providers by weight-loss efficacy. A transparent process deserves recognition, but transparency and demonstrated clinical performance remain separate judgments.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

What Public GLP-1 Provider Documents Can—and Cannot—Prove

At a glance

01Start with the claim, not the logo

02Map who actually performs each service

03Treat enrollment steps as process evidence

04Read prices as conditional offers, not clinical evidence

05Use contradictions to identify unresolved obligations

06Keep clinical studies separate from provider performance

07Ask what testing and shipping claims leave out

08Distinguish an open messaging channel from ongoing care